A fund managed by JIC Venture Growth Investments now holds 6.97% of Cuorips (ticker 4894) after buying 619,700 new shares at ¥4,841 each on 28 September 2026. The purchase was a third-party allotment, an off-market acquisition, according to a large-shareholding report filed on 2 October.
The stake
The report names the JICVGI Opportunity Fund No. 1 investment limited partnership as the vehicle, with JIC Venture Growth Investments as its general partner. The filer counts the shares under the provision covering holdings by a fund of which it is general partner. Japan's large-shareholding rule requires a report to the finance ministry's local bureau once a holder passes 5% of a listed company; this one went to the Kanto Local Finance Bureau chief.
The 6.97% figure is measured against 8,893,076 shares outstanding as of 28 September 2026. The report lists the fund's holding at 619,700 shares and no latent shares such as warrants or convertible bonds. It leaves the prior-holding ratio blank, so it does not describe a change from an earlier position.
Price and funding
The report puts the total acquisition cost at ¥2,999,968 thousand, or about ¥3bn. It classes the money as "other" funding, which it describes as the fund's operating capital. No borrowing is listed, and no lender is named.
The filer gives its holding purpose as pure investment and reports no significant proposal activity. In practice that means the filing describes a financial holding with no stated plan to press management on strategy, board seats or capital policy.
Where it fits
Cuorips is the Tokyo-listed company that won an insurance listing for its ReHeart product at ¥53.2mn per treatment, as Tokyo Brief reported in September. This filing adds an investor to the register after that listing. The report does not say why Cuorips issued the shares or how the company will use the proceeds.